Wegovy may generate more than $4 billion in revenue this year for Novo Nordisk. A recent study showed the weight-loss drug can also help people bring down their risk of heart attack or stroke.

The European Medicines Agency (EMA) said on Monday Eli Lilly & Co's Trulicity, which treats type 2 diabetes in children above 10 years of age, will continue to remain in shortage in Europe through ...

Growth stocks continue to drive both the stock market and investors' portfolios. Game-changing growth stocks to buy that have multi-year catalysts to drive their earnings and share price steadily h...

Eli Lilly settled another age discrimination lawsuit for an undisclosed amount, just two months after reaching a $2.4 million settlement with the EEOC.

A new study by Novo Nordisk points to GLP-1 drugs reducing cardiac risks. It's a relevant finding for Eli Lilly, too, which is already moving forward in clinical trials.

Novo Nordisk and Eli Lilly want to use their medicines to treat NASH, a liver disease. Their chances of success are more uncertain than shareholders might wish to see.

Eli Lilly & Co. LLY, +0.66% on Tuesday reported positive results from a study evaluating its targeted therapy Retevmo versus the current standard initial treatments for patients with advanced or me...

Eli Lilly has explosive growth potential. Novo Nordisk is worth its premium price tag.

Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.

Eli Lilly's sales growth last quarter was driven in large part by three drugs. Trulicity remains the company's top seller, but it might not stay that way for long.

Eli Lilly's newest diabetes therapy is meeting its lofty expectations. Some of the company's other medicines are also performing well.

Eli Lilly shares hit an all-time high as the drugmaker closed two acquisitions, including one related to the hot market for weight-loss treatments.

Eli Lilly and Company reported a superb Q2, triggering a sharp price rally and pushing its valuation to a very concerning level in my view. There are certainly plenty to be optimistic about, rangin...

The 'Fast Money' traders talk Eli Lilly's stellar trading week and how to play the stock moving forward.

Diabetes therapy Mounjaro paced the company's revenue growth. Lilly raised full-year guidance for revenue and earnings per share.